发明公开
EP3077390A1 CRYSTALLINE SALT FORM OF (S)-(2-(6-CHLORO-7-METHYL-1 H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1 -YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AS OREXIN RECEPTOR ANTAGONIST 有权
(S) - (2-(6-氯-7-甲基-1H-苯并[d]咪唑烷-2-基)-2-甲基吡咯烷-1-基)(5-甲氧基-2-(2H- 1,2,3-TRIAZOL-2-YL)苯甲酸甲酯副产物

CRYSTALLINE SALT FORM OF (S)-(2-(6-CHLORO-7-METHYL-1 H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1 -YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AS OREXIN RECEPTOR ANTAGONIST
摘要:
The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1 H-benzo[d]imidazol- 2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
信息查询
0/0